SOMATOSTATIN ANALOGUES: FROM RESEARCH TO CLINICAL PRACTICE

Contributors viii
Preface xii
Acknowledgements xv
1 Somatostatin: The History of Discovery 1
2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6
3 Somatostatin Receptors in Malignancies and Other Pathologies 21
4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31
4.1 Somatostatin Receptor Scintigraphy-SPECT 35
4.2 Molecular Imaging of Somatostatin Receptor-Positive Tumors Using PET/CT 55
4.3 Other Radiopharmaceuticals for Imaging GEP-NET 75
4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86
4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90
4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112
4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127
4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135
4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153
5 Somatostatin Analogues in Pharmacotherapy: Introduction 164
5.1 Somatostatin Analogues in Pharmacotherapy 166
5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169
5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189
5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198
6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207
6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214
6.2 PRRT Dosimetry 230
6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252
6.4 Duo-PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y-90- and Lu-177-Labeled Somatostatin Analogues 264
6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273
6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282
7 Somatostatin Analogs: Future Perspectives and Preclinical Studies—Pansomatostatins 291
8 Radiolabeled Somatostatin Receptor Antagonists 305
9 Cortistatins and Dopastatins 321
Index 000

Featuring chapters from specialists in endocrinology, physiology, pathology, and nuclear medicine, this book provides a multidisciplinary approach to a wide variety of issues concerning somatostatin and its analogues. The book:

- Provides the most up-to-date coverage of somatostatin analog use in diagnostic and therapy
- Integrating the specialties of endocrinology, physiology, pathology, and nuclear medicine, providing the multidisciplinary approach to the topic
- Focuses on future applications, novel compounds, and areas for further research
- Covers topics by authors who are renowned experts and researchers in the field

Author Information

Alicja Hubalewska-Dydejczyk, PhD, MD, is Professor of Endocrinology and Nuclear Medicine, and Head of the Chair and Department of Endocrinology at the Jagiellonian University's Medical College (Cracow, Poland).

Alberto Signore, MD, is Professor of Nuclear Medicine and Physician in the Department of Medical-Surgical Sciences and Translational Medicine of the Faculty of Medicine and Psychologu of "Sapienza" University in Rome, Italy.

Marion de Jong, PhD, is Professor of Nuclear Biology at the Departments of Nuclear Medicine and Radiology of the Erasmusc MC in Rotterdam, The Netherlands.

Rudi A. Dierckx, PhD, is Head of the Department of Nuclear Medicine and Molecular Imaging at the University Medical Center Groningen, University of Groningen, the Netherlands.

John Buscombe, MD, is a Consultant Physician in Nuclear Medicine Addenbrooke's Hospital (Cambridge, UK) and Honorary Professor in Nuclear Medicine at the University of Pretoria, South Africa.

Christophe Van de Wiele, PhD, is Full Professor at the University of Ghent, Belgium.